Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Tang-Du Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Fujian Medical University Union Hospital
West China Hospital
Peking University Cancer Hospital & Institute
Nanjing First Hospital, Nanjing Medical University
Sun Yat-sen University
Hebei Medical University Fourth Hospital
Guangdong Association of Clinical Trials
Ludwig Institute for Cancer Research
Sichuan University
Sun Yat-sen University